亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease

医学 托法替尼 间质性肺病 皮肤病科 皮肌炎 肺 内科学 类风湿性关节炎
作者
Zhiwei Chen,Xiaodong Wang,Shuang Ye
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:381 (3): 291-293 被引量:372
标识
DOI:10.1056/nejmc1900045
摘要

Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung DiseaseTo the Editor: Anti-melanoma differentiationassociated protein (MDA) 5 (anti-MDA5)-positive amyopathic dermatomyositis (ADM)-associated interstitial lung disease (ILD) (hereafter, ADM-ILD) is a rapidly progressive and life-threatening disease. 1 Despite aggressive conventional treatments with high-dose glucocorticoids in combination with cyclosporine, tacrolimus, or cyclophosphamide, the 6-month mortality is as high as 50%. 2,3Japanese investigators recently reported the possible efficacy of tofacitinib, a Janus kinase (JAK) inhibitor, as a rescue option for patients with high-risk ADM-ILD after failure of conventional treatment. 3 Our data have also suggested that a JAK inhibitor could abrogate the proinflammatory and profibrotic effects of ADM-ILDderived T cells in vitro. 4 Thus, we conducted a single-center, open-label clinical study (Chinese Clinical Trial Registry number, ChiCTR-1800016629) to evaluate the efficacy of tofacitinib in patients with early-stage anti-MDA5positive AMD-ILD.Patients were included in the trial if they were older than 18 years of age, met the criteria for a diagnosis of ADM 2 and were positive for anti-MDA5 antibodies, had had ILD (confirmed by pulmonary high-resolution computed tomography [CT]) for less than 3 months, and had a predicted forced vital capacity (FVC) of at least 50%.Patients were excluded if they had other connective-tissue diseases, an underlying cancer, a concomitant infection, or a liver aminotransferase level greater than 2 times the upper limit of the normal range.From July 2017 through September 2018, a total of 18 consecutive patients who were eligible to participate in the trial were prospectively enrolled at our center and received a glucocorticoid
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
萧雨墨发布了新的文献求助10
2秒前
完美世界的应助被Jerry采纳,获得10
2秒前
2秒前
一葵完成签到 ,获得积分10
3秒前
单薄的誉完成签到,获得积分10
3秒前
CipherSage的应助被花海采纳,获得10
4秒前
5秒前
盼月来完成签到 ,获得积分10
5秒前
uri完成签到 ,获得积分10
5秒前
wwwww完成签到,获得积分10
6秒前
7秒前
白芷完成签到 ,获得积分10
8秒前
9秒前
Log发布了新的文献求助10
9秒前
10秒前
huahuahua发布了新的文献求助10
10秒前
asr发布了新的文献求助10
11秒前
赟糖完成签到 ,获得积分10
12秒前
14秒前
欢呼的馒头完成签到,获得积分10
15秒前
zkygmu发布了新的文献求助10
15秒前
18秒前
阴天完成签到 ,获得积分10
19秒前
haoliu完成签到,获得积分10
20秒前
huahuahua发布了新的文献求助10
23秒前
Orange的应助被zkygmu采纳,获得10
25秒前
28秒前
萧雨墨完成签到,获得积分10
30秒前
31秒前
ance发布了新的文献求助10
32秒前
EricSai发布了新的文献求助10
34秒前
34秒前
su完成签到,获得积分10
35秒前
36秒前
白华苍松发布了新的文献求助20
36秒前
36秒前
想活在梦里完成签到,获得积分10
36秒前
37秒前
郭浩瑞完成签到,获得积分20
37秒前
huahuahua发布了新的文献求助10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190026
求助须知:如何正确求助?哪些是违规求助? 9577160
关于积分的说明 21851766
捐赠科研通 7788109
什么是DOI,文献DOI怎么找? 3435873
关于科研通互助平台的介绍 2559910
邀请新用户注册赠送积分活动 2482761